MYGN: Myriad Genetics, Inc. - Summary | Jitta

Myriad Genetics, Inc.

NASDAQ:MYGN

End of day
Dec 14, 2018
Price
$31.15
Loss Chance
51.1%
4.95
Updated 2019Q1
last month
Nov 08, 2018
JITTA SCORE
54.79%Above Jitta Line
Jitta Ranking
133 / 795
United States
?
NASDAQ, NYSE
1,957 / 4,758
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (18)
Recent Business Performance (52)
Financial Strength (82)
Return to Shareholders (42)
Competitive Advantage (69)
Jitta Signs
Recent Business Performance
Earning per ShareQ1Q2Q3Q4
20190.07---
20180.142.090.150.09
2017-0.010.090.090.15
Earning Growth Last Year
Debt Level
20142015201620172018
Net Profit (mill.)176.7780.50117.2023.3562.57
Long Term Debt (mill.)0.000.000.0099.109.30
Low Long Term Debt
CapEx
20142015201620172018
CapEx per Share0.190.350.070.090.12
Earning per Share2.411.171.700.340.89
Very Low
Revenue and Earning
201320142015201620172018
Revenue7.6110.5910.4910.7211.2610.94
EPS1.832.411.171.700.340.89
Earning decline from 2015-2018
Operating Margin
20142015201620172018
Operating Margin (%)35.2618.5620.726.227.44
Inconsistent
Recent Business Performance
Earning per ShareQ1Q2Q3Q4
20190.07---
20180.142.090.150.09
2017-0.010.090.090.15
Earning decline 50.72% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
4.95
54.79%
1.82
0.85%
2.44
0.48%
Biotechnology
COMPANY DESCRIPTION
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.